Dual inhibitors of hepatitis C virus and hepatocellular carcinoma: design, synthesis and docking studies.

Autor:	El-Miligy MM; Pharmaceutical Chemistry Department, Faculty of Pharmacy, Alexandria University, Alexandria 21521, Egypt.; Pharmaceutical Chemistry Department, Faculty of Pharmacy, Alexandria University, Alexandria 21521, Egypt., Rida SM; Pharmaceutical Chemistry Department, Faculty of Pharmacy, Alexandria University, Alexandria 21521, Egypt.; Pharmaceutical Chemistry Department, Faculty of Pharmacy, Alexandria University, Alexandria 21521, Egypt., Ashour FA; Pharmaceutical Chemistry Department, Faculty of Pharmacy, Alexandria University, Alexandria 21521, Egypt.; Pharmaceutical Chemistry Department, Faculty of Pharmacy, Alexandria University, Alexandria 21521, Egypt., Badr MH; Pharmaceutical Chemistry Department, Faculty of Pharmacy, Alexandria University, Alexandria 21521, Egypt.; Pharmaceutical Chemistry Department, Faculty of Pharmacy, Alexandria University, Alexandria 21521, Egypt., El-Bassiony EM; Pharmaceutical Chemistry Department, Faculty of Pharmacy, Alexandria University, Alexandria 21521, Egypt.; Pharmaceutical Chemistry Department, Faculty of Pharmacy, Alexandria University, Alexandria 21521, Egypt., El-Demellawy MA; Medical Biotechnology Department, Genetic Engineering & Biotechnology Research Institute, City for Scientific Research & Technology Applications, Alexandria, Egypt.; Medical Biotechnology Department, Genetic Engineering & Biotechnology Research Institute, City for Scientific Research & Technology Applications, Alexandria, Egypt., Omar AM; Medical Biotechnology Department, Genetic Engineering & Biotechnology Research Institute, City for Scientific Research & Technology Applications, Alexandria, Egypt.; Medical Biotechnology Department, Genetic Engineering & Biotechnology Research Institute, City for Scientific Research & Technology Applications, Alexandria, Egypt.
Jazyk:	angličtina
Zdroj:	Future science OA [Future Sci OA] 2017 Oct 25; Vol. 4 (1), pp. FSO252. Date of Electronic Publication: 2017 Oct 25 (Print Publication: 2018).
DOI:	10.4155/fsoa-2017-0075
Abstrakt:	Aim: Simultaneous inhibition of hepatitis C virus (HCV) and hepatocellular carcinoma (HCC) may enhance anti-HCV effects and reduce resistance and side effects. Results/methodology: Novel hybrid derivatives were designed and synthesized to exhibit dual activity against HCV and its associated major complication, HCC. The synthesized compounds were screened for their potential activity against HCV and HCC. Compounds 5f, 5j, 5l, 5p, 5q, 5r, 6c and 6d exhibited potential in vitro anticancer activity against HCC cell line HepG2, while compounds 5a, 5l, 5p and 5v showed in vitro anti-HCV activity. Docking studies suggested that the newly synthesized compounds could suppress HCC through VEGFR2 tyrosine kinase inhibition. Conclusion: Compounds 5l and 5p exhibited dual activity against HCV and HCC in vitro . Competing Interests: Financial & competing interests disclosure This work was financially supported by funds from Alexandria University Research Fund (AURF); Research Enhancement Program (ALEX REP) as a part of the project entitled ‘Design, synthesis and molecular modeling study of novel benzofurans and their bioisosteres as HCV and tumor inhibitors’ (code: HLTH-10). MMM El-Miligy, SM Rida, FA Ashour, MH Badr and EM El-Bassiony are full-time employees of Pharmaceutical Chemistry Department, Faculty of Pharmacy, Alexandria University, Alexandria, Egypt. MA El-Demellawy and AM Omar are full-time employees of Genetic Engineering and Biotechnology Research Institute (GEBRI), City for Scientific Research and Technology, Alexandria, Egypt. The authors have no other relevant affiliations or financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the manuscript apart from those disclosed. No writing assistance was utilized in the production of this manuscript.
Databáze:	MEDLINE
Externí odkaz:	Zobrazit plný text záznamu